The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The need for more effective, less toxic therapies in frontline DLBCL treatment
In this video, Jennifer Amengual, MD, Columbia University Irving Medical Center, New York City, NY, discusses the need to improve treatment approaches for patients with diffuse large B-cell lymphoma (DLBCL) in the frontline setting. Dr Amengual explains that chemotherapy remains the backbone of treatment in this disease, and further highlights novel strategies being explored to reduce patient exposure to toxic chemotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
